• Energy Research
• DE close
• EU close
• Neuroinformatics close

AbstractObjective: The marked increase in the prevalence of obesity in the United States has recently been attributed to the increased fructose consumption. To determine if and how fructose might promote obesity in an animal model, we measured body composition, energy intake, energy expenditure, substrate oxidation, and several endocrine parameters related to energy homeostasis in mice consuming fructose.Research Methods and Procedures: We compared the effects of ad libitum access to fructose (15% solution in water), sucrose (10%, popular soft drink), and artificial sweetener (0% calories, popular diet soft drink) on adipogenesis and energy metabolism in mice.Results: Exposure to fructose water increased adiposity, whereas increased fat mass after consumption of soft drinks or diet soft drinks did not reach statistical significance (n = 9 each group). Total intake of energy was unaltered, because mice proportionally reduced their caloric intake from chow. There was a trend toward reduced energy expenditure and increased respiratory quotient, albeit not significant, in the fructose group. Furthermore, fructose produced a hepatic lipid accumulation with a characteristic pericentral pattern.Discussion: These data are compatible with the conclusion that a high intake of fructose selectively enhances adipogenesis, possibly through a shift of substrate use to lipogenesis.

Abstract Aims Alcohol use alters the reward signaling processes contributing to the development of addiction. We studied the effects of alcohol use disorder (AUD) on brain regions and blood of deceased women and men to examine sex-dependent differences in epigenetic changes associated with AUD. We investigated the effects of alcohol use on the gene promoter methylation of GABBR1 coding for GABAB receptor subunit 1 in blood and brain. Methods We chose six brain regions associated with addiction and the reward pathway (nucleus arcuatus, nucleus accumbens, the mamillary bodies, amygdala, hippocampus and anterior temporal cortex) and performed epigenetic profiling of the proximal promoter of the GABBR1 gene of post-mortem brain and blood samples of 17 individuals with AUD pathology (4 female, 13 male) and 31 healthy controls (10 female, 21 male). Results Our results show sex-specific effects of AUD on GABBR1 promoter methylation. Especially, CpG −4 showed significant tissue-independent changes and significantly decreased methylation levels for the AUD group in the amygdala and the mammillary bodies of men. We saw prominent and consistent change in CpG-4 across all investigated tissues. For women, no significant loci were observed. Conclusion We found sex-dependent differences in GABBR1 promoter methylation in relation to AUD. CpG-4 hypomethylation in male individuals with AUD is consistent for most brain regions. Blood shows similar results without reaching significance, potentially serving as a peripheral marker for addiction-associated neuronal adaptations. Further research is needed to discover more contributing factors in the pathological alterations of alcohol addiction to offer sex-specific biomarkers and treatment.

The steady state levels of the messenger RNA (mRNA) of eight GABAA receptor subunits, five glutamate receptor subunits and seven enzymes involved in the synthesis of glutamate and GABA were measured in eight regions of rat brain in a recently developed animal model of ‘behavioural dependence’ on ethanol. ‘Behavioural dependence’ including loss of control was induced by offering the rats the choice between ethanol and water over a 9‐month period (Group A). This group was compared with a group given the choice between ethanol and water for only 2 months (not yet ‘behaviourally dependent’, Group B), a group forced to consume ethanol as sole fluid over a 9‐month period (also not ‘behaviourally dependent’, Group C) and ethanol‐naive control rats (Group D). All groups were sacrificed 1 month after the ethanol was withdrawn. The mRNA concentrations of all eight GABA receptor subunits, four out of the five subunits of different glutamate receptors and those of seven enzymes involved in GABA and glutamate production were reduced almost exclusively in the parieto‐occipital cortex in Groups A and B, but not Group C. These data suggest that the synthesis of glutamate and GABA and the activities of their respective neurons are selectively impaired in the parieto‐occipital cortex in the groups having consumed ethanol in a free‐choice design, in which its rewarding properties can better take effect than after forced administration. As the parieto‐occipital cortex is believed to contain emotional memory structures, it may be hypothesized that the glutamatergic and GABAergic neuronal systems in this area are involved in the development of memory for reward from ethanol. However, they are not specifically associated with ‘behavioural dependence’. British Journal of Pharmacology (2000) 131, 423–432; doi:10.1038/sj.bjp.0703596

Citalopram, a selective 5-HT uptake inhibitor with antidepressant properties, was assessed in three studies in 12 healthy subjects using a battery of EEG, psychological, subjective and symptomatic measures. Study A involved the administration of citalopram, 20 mg and 40 mg, amitriptyline 50 mg and placebo in single dose using a balanced cross-over design. The test battery was applied before, and 1 and 3 h after each drug. Citalopram decreased slow-wave EEG activity whereas amitriptyline increased power in most EEG wavebands. Citalopram increased tapping rate and symbol copying whereas amitriptyline impaired these and other psychomotor tasks. Subjectively, amitriptyline was much more sedative than citalopram and produced more complaints of dry mouth. Study B comprised the administration of citalopram in the usual clinical dose of 40 mg, amitriptyline in the low clinical dose of 75 mg and placebo, each given for 9 nights using a balanced cross-over design. The test battery was applied on the first morning (pre-drug) and on the morning after the last nightly dose. None of the physiological tests showed any drug effects. Subjectively, citalopram was associated with feelings of shaking, nausea, loss of appetite and physical tiredness; amitriptyline produced feelings of shaking, nausea, loss of appetite, dryness of mouth, irritability, dizziness and indigestion; in general, amitriptyline effects were more marked than those of citalopram. Plasma samples were taken on the last day and plasma concentrations of both drugs and their metabolites were found to be in the expected range for the regimens used.(ABSTRACT TRUNCATED AT 250 WORDS)

BACKGROUND: On the subject of cerebral infarction, it is a common saying that “time is brain”. The prognosis of a patient who has received thrombolysis after such an infarction becomes significantly better as the time from symptom debut until the thrombolytic bolus lessens. Identifying the factors that contribute to longer times before thrombolysis for patients could thus be meaningful, and this is exactly what the aim of this assignment is. METHODS: Data was collected from the digital documents of patients who had received thrombolytic treatment from Akershus University Hospital. Both linear and categorical variables were registered from fields such as the patients’ background, vitals and disease severity. Time from onset to arrival at the hospital and time from arrival to the start of the infusion were registered in detail, and potentially delaying factors such as uncertain time of symptom debut and suspected contraindications were explored. The official Norwegian limit for delayed thrombolysis is 40 minutes, and thus this was chosen as the limit in this assignment as well. RESULTS: A total of 100 patients were registered, having received thrombolysis in 2015 and 2016. 50 men and 50 women were registered, with a mean age of 67.6. The mean NIHSS on arrival was 7.63 (standard variance 6.06). The mean time from symptom debut until arrival was 90.09 min (standard variance 48.91) and the mean time from arrival until the thrombolysis was given was 46.24 min (standard variance 33.40). 48.0% of the patients received thrombolysis more than 40 min after arrival, thus defining it as delayed treatment. The factors which showed a significant association with delayed treatment, using a confidence interval of 95%, were smoking (p=0.028), necessary prethrombolytic reduction in blood pressure (p=0.002), suspected contraindication (p=0.023) and uncertain severity of disease (p=0.001). Factors that unexpectedly showed no significant association with delayed treatment were uncertain time of symptom debut and high NIHSS on arrival. CONCLUSION: Factors that may have contributed to delayed thrombolysis were smoking, prethrombolytic reduction of blood pressure, suspected contraindications and uncertain severity of disease. In order to shorten the time from arrival to treatment, the effects of these factors on the efficiency of the thrombolytic procedure must be minimized. This could be attempted by using tools such as stricter, clearer guidelines and hospital campaigns targeting the attitudes of the personnel. All this being said, this assignment has made it clear that the treatment of cerebral infarctions is largely successful.

A target-pattern-driven (TD) trajectory design is introduced in combination with parallel transmit (pTX) radiofrequency (RF) pulses to provide localized suppression of unwanted signals. The design incorporates target-pattern and B1+ information to adjust denser sampling and coverage in k-space regions where the main pattern information lies. Based on this approach, two-dimensional RF spiral saturation pulses sensitive to RF power limits were applied in vivo for the first time.The TD method was compared with two state-of-the-art spiral design methods. Simulations at different spatial fidelities, acceleration factors and anatomical regions were carried out for an eight-channel pTX 3 Tesla (T) coil. Human in vivo experiments were performed on a two-channel pTX 3T scanner saturating shaped patterns in the brain, heart, and thoracic spine.Using the TD trajectory, RF pulse power can be substantially reduced by up to 34% compared with other trajectory designs with the same spatial accuracy. Local and global specific absorption rates are decreased in most cases.The TD trajectory design uses available a priori information to enhance RF power efficiency and spatial response of the RF pulses. Shaped saturation pulses show improved spatial accuracy and saturation performance. Thus, RF pulses can be designed more efficiently and can be further accelerated.

The isolated perfused rat brain was used for a comparative study of the effects of chloral hydrate and trichloroethanol on cerebral energy metabolism. After a perfusion period of 30 min the brain levels of the following substrates and metabolites were measured spectrophotometrically: P-creatine, creatine, ATP, ADP, AMP, glycogen, glucose, glucose-6-P, fructose diphosphate, α-glycero-P, dihydroxyacetone-P, pyruvate, lactate, glutamate, α-ketoglutarate and ammonia. Furthermore, the concentration of chloral hydrate and trichloroethanol in the isolated brain and in the perfusion medium was measured colorimetrically. Little more than 10% of chloral hydrate in the isolated brain and in the perfusion medium were reduced to trichloroethanol. In intact animals there were about 70% of chloral hydrate transformed. Chloral hydrate and trichloroethanol caused an accumulation of P-creatine, no change in the lactate/pyruvate ratio, an increase of the glucose concentration and a decrease of glucose-6-P level in the isolated brain. The rise of brain glucose level was more pronounced after trichloroethanol than after chloral hydrate. The effects of chloral hydrate and trichloroethanol on brain glucose and glucose-6-P levels suggest an inhibition of brain hexokinase activity by these drugs.

In the immature mammalian brain during a period of rapid growth (brain growth spurt/synaptogenesis period), neuronal apoptosis can be triggered by the transient blockade of glutamate N-methyl-d-aspartate (NMDA) receptors, or the excessive activation of gamma-aminobutyric acid (GABA(A)) receptors. Apoptogenic agents include anesthetics (ketamine, nitrous oxide, isoflurane, propofol, halothane), anticonvulsants (benzodiazepines, barbiturates), and drugs of abuse (phencyclidine, ketamine, ethanol). In humans, the brain growth spurt period starts in the sixth month of pregnancy and extends to the third year after birth. Ethanol, which has both NMDA antagonist and GABA(A) agonist properties, is particularly effective in triggering widespread apoptotic neurodegeneration during this vulnerable period. Thus, maternal ingestion of ethanol during the third trimester of pregnancy can readily explain the dysmorphogenic changes in the fetal brain and consequent neurobehavioral disturbances that characterize the human fetal alcohol syndrome. In addition, there is basis for concern that agents used in pediatric and obstetrical medicine for purposes of sedation, anesthesia, and seizure management may cause apoptotic neuronal death in the developing human brain.